Form 4: Inhibrx Biosciences CEO Mark Lappe Increases Stake in Company
SEC Form 4 Filing
Inhibrx Biosciences CEO Mark Lappe reports purchasing additional shares of the company's common stock through the Lappe Family Trust.
Summary
- Mark Lappe, CEO of Inhibrx Biosciences, has reported changes in his beneficial ownership of the company's stock.
- On September 6, 2024, the Lappe Family Trust acquired 26,000 shares of common stock at a weighted average price of $15.29 per share.
- On September 9, 2024, the Lappe Family Trust acquired 9,500 shares of common stock at a weighted average price of $15.21 per share.
- On September 10, 2024, the Lappe Family Trust acquired 8,500 shares of common stock at a weighted average price of $15.19 per share.
- Following these transactions, the Lappe Family Trust beneficially owns 665,548 shares.
- Lappe also indirectly beneficially owns 165,000 shares through the Lappe Descendants' Trust and 54,865 shares through The Mark Paul Lappe Roth IRA.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the CEO's increased investment in the company, which is generally viewed as a sign of confidence. However, it's important to consider the size of the purchases relative to the CEO's existing holdings and the overall market capitalization of the company.
Positives
- The CEO's increased investment in the company may signal confidence in its future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that company leadership believes the stock is undervalued or that the company's prospects are strong.
Stakeholder Impact
- Shareholders may view the CEO's stock purchases as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 09/06/2024 | Lappe Family Trust acquired 26,000 shares of Inhibrx Biosciences common stock. |
| 09/09/2024 | Lappe Family Trust acquired 9,500 shares of Inhibrx Biosciences common stock. |
| 09/10/2024 | Lappe Family Trust acquired 8,500 shares of Inhibrx Biosciences common stock. |
| 09/10/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.